Who are Mizoribine (MZR)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sirolimus (drug), mmf (drug), Mycophenylate mofetil, Mycophenolate mofetil Tab./Cap., Mycophenolic Acid (MPA), Placebo to Mycophenolate mofetil, Mycophenolic Acid Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mizoribine-mzr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mizoribine (MZR) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mizoribine (MZR) (Mizoribine (MZR)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IMPDH inhibitor; immunosuppressant. Area: Immunology; Transplantation.

phase 3 IMPDH inhibitor; immunosuppressant IMPDH (inosine monophosphate dehydrogenase) Immunology; Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Mizoribine (MZR) (Mizoribine (MZR)) — Asahi Kasei Pharma Corporation. Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mizoribine (MZR) TARGET	Mizoribine (MZR)	Asahi Kasei Pharma Corporation	phase 3	IMPDH inhibitor; immunosuppressant	IMPDH (inosine monophosphate dehydrogenase)
sirolimus (drug), mmf (drug)	sirolimus (drug), mmf (drug)	University Hospital Muenster	marketed	Immunosuppressive agents (mTOR inhibitor + IMPDH inhibitor combination)	mTOR (sirolimus); IMPDH type II (MMF)
Mycophenylate mofetil	Mycophenylate mofetil	Masonic Cancer Center, University of Minnesota	marketed	Immunosuppressant, IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolate mofetil Tab./Cap.	Mycophenolate mofetil Tab./Cap.	Chong Kun Dang Pharmaceutical	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid (MPA)	Mycophenolic Acid (MPA)	Novartis	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Placebo to Mycophenolate mofetil	Placebo to Mycophenolate mofetil	Hoffmann-La Roche	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid Oral Product	Mycophenolic Acid Oral Product	Simon Tremblay, PharmD, PhD	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IMPDH inhibitor; immunosuppressant class)

Asahi Kasei Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mizoribine (MZR) — Competitive Intelligence Brief. https://druglandscape.com/ci/mizoribine-mzr. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab